Aspira Women`s Health Inc Stock Price, News & Analysis

Aspira Women’s Health Inc. (Nasdaq: AWH) announced a public offering of 6,000,000 shares at $7.50 per share, with a potential increase of 900,000 shares via underwriter option. The offering, managed by William Blair & Company and Truist Securities, aims to raise approximately $45 million, potentially $51.75 million if the option is fully exercised. Funds will support sales, marketing, working capital, and R&D. The offering is set to close on February 8, 2021. The shares are offered under an effective shelf registration statement with the SEC.

Aspira Women’s Health Inc. (Nasdaq: AWH) has initiated an underwritten public offering of its common stock, with market conditions influencing its completion. The offering will include a 30-day underwriter option for an additional 15% of shares. Proceeds are intended for sales and marketing, working capital, strategic hires, product expansion, and potential acquisitions. The offering is backed by a previously filed shelf registration statement with the SEC, though no specific commitments for acquisitions are currently in place.

Aspira Women’s Health Inc. (Nasdaq: AWH) has announced its expansion as a participating laboratory network provider for Highmark’s commercial health insurance products in Pennsylvania and West Virginia. This initiative will enhance access to OVA1® and OVERA® tests, which assess ovarian malignancy risks in women with adnexal masses. Aspira now provides network access to over 154 million individuals, crucial for improving healthcare access for women, according to CEO Valerie Palmieri. The company aims to close ethnic disparities in ovarian cancer risk assessment and advance gynecologic health outcomes.

Aspira Women’s Health (Nasdaq: AWH) will participate in the 10th Annual LifeSci Advisors Corporate Access Event from January 6-8 and 11-14, 2021, along with the 2021 Biotech Showcase from January 11-15. Management, including President Valerie Palmieri and CFO Robert Beechey, will hold 1x1 meetings and present on Innovations in Cancer Diagnostics on January 7. The conference aims to foster investor relationships and partnerships in therapeutic development. More details and registration links are available in the full announcement.

Aspira Women's Health, Inc. (Nasdaq: AWH) has partnered with Baylor Genetics to co-develop a novel early-detection test for ovarian cancer, which has a mortality rate exceeding 50%. This collaboration aims to leverage both companies' strengths, focusing on the OVA360 clinical study to establish an ovarian cancer molecular profile. Aspira brings over a decade of experience in ovarian cancer detection and has developed multiple FDA-cleared products, while Baylor Genetics contributes advanced genomic testing expertise. The partnership seeks to enhance early detection and improve clinical outcomes for women.

Aspira Women’s Health Inc. (AWH) reported strong financial results for Q3 2020, with product revenue of $1.2 million, a 68% increase from Q2 2020. Test volume has rebounded to 95% of pre-COVID levels, aided by a new CIGNA contract, expanding payer coverage, and an increase in pricing. OVA1 test volume grew 46% sequentially, and 84% of its customers were repeat physicians. The company added key executives to its leadership team, emphasizing its commitment to women's health. Cash balance stood at approximately $19 million.

Aspira Women’s Health appoints five new executives to enhance its focus on women’s health and tackle ovarian cancer. The new leadership team includes experienced professionals from various healthcare sectors, aiming to accelerate innovation and growth. Notable appointments include Dr. Elena Ratner as Global Chief Medical Advisor and Kaile Zagger as Chief Operating Officer. The company seeks to improve gynecologic cancer detection and risk management, aligning with its mission to support women of all backgrounds. Aspira’s advancements position it favorably in the growing market for cancer diagnostics.

Aspira Women’s Health, Inc. (Nasdaq: AWH) has appointed Dr. Sandra E. Brooks to its Board of Directors, enhancing its leadership team amid growth. With a strong background as a gynecologic oncologist and physician executive, Dr. Brooks brings valuable insights to the company as it aims to expand into larger healthcare systems and address gynecologic diseases. This change increases the Board's female representation to a majority, reflecting the company's commitment to diversity. Aspira focuses on innovative testing solutions to improve women's health, particularly in ovarian cancer risk assessment.

Aspira Women’s Health, Inc. (Nasdaq: AWH) announced its participation in the Canaccord Genuity Virtual MedTech & Diagnostics Forum on November 19, 2020, at 9:00 AM ET. The presentation will be webcast live, with registration details available on their website. Aspira is focused on innovative testing for women’s health, specifically in ovarian cancer risk assessment and pelvic diseases. Their product portfolio includes FDA-cleared options like OVA1® and OVERA®. The company aims to address ethnic disparities in health outcomes through advanced bioanalytical solutions.